Pheochromocytoma
1 paper
Trial sponsors
European Organisation for Research and Treatment of Cancer - EORTC
2 trialsPhase 3690 people
National Cancer Institute, Egypt
1 trialPhase 230 people
1 trialPhase 230 people
1 trialPhase 118 people
Latest
1 in 12 monthsENDO 2025 Abstract
MON-005 AN UNUSUAL CASE OF VASOMOTOR SYMPTOMS IN A POST-MENOPAUSAL WOMAN
Case reportMechanisms
Journal of Neuroimmune Pharmacology
Temporin-1CEa and its Analog LK2(6)A(L) Confer Neuroprotective Effects in Parkinson's Disease Model by Attenuating Neuroinflammation Via the NF-κB and MAPK Signaling Pathways
Experiments in wormsParkinson's disease